Avizakimab, formerly known as BOS161721, represents a innovative clinical approach to treating autoimmune conditions . This antibody agent selectively targets IL18, a key protein implicated in the pathogenesis of several serious illnesses. Preclinical data have shown Avizakimab’s capacity to effectively suppress IL-18 function , leading to decrea

{Atacicept | VT-001: A Novel Therapeutic Atacicept, also known as the VT-001 agent, represents a compelling advance in therapeutic science. This innovative substance functions as a decoy molecule, effectively neutralizing the activity of TNFSF-13 , a key component in B-cell longevity and antibody production. Initial clinical studies have shown